Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gilead Sciences
AstraZeneca
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
AstraZeneca
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Massachusetts General Hospital
Big Ten Cancer Research Consortium
Mayo Clinic
Lantern Pharma Inc.
University of Kentucky
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
BeiGene
Masonic Cancer Center, University of Minnesota
University Hospital, Essen
Alliance for Clinical Trials in Oncology
ImmunoGenesis
Bristol-Myers Squibb
Fundación GECP
Fox Chase Cancer Center
Fundación GECP
EpicentRx, Inc.
Sun Yat-sen University
Massachusetts General Hospital
Shanghai Chest Hospital
BeiGene
SWOG Cancer Research Network
Rutgers, The State University of New Jersey
M.D. Anderson Cancer Center
University of Washington
Barbara Ann Karmanos Cancer Institute
National Hospital Organization Nagoya Medical Center
Hoosier Cancer Research Network
SCRI Development Innovations, LLC
University of California, San Francisco
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Chonnam National University Hospital
Barbara Ann Karmanos Cancer Institute
Massachusetts General Hospital
Dutch Society of Physicians for Pulmonology and Tuberculosis
Mereo BioPharma
University of Maryland, Baltimore
Eli Lilly and Company
Eli Lilly and Company